中文网站正在持续更新中,请密切关注我们康肽生物的最新动态,或点击访问右上角的英文官方网站 www.phoenixpeptide.com
PHOENIX PHARMACEUTICALS, INC. TOP HOME PAGE
Top Catalog English Version | My Account | 联系我们 | China



 多肽



 标记多肽 



 多肽激素文库



 抗体 



 免疫试剂盒 



 生物标志物阵列 



 多肽样品检测



 自定义肽链合成及GMP



 产品目录索取



 样品准备



 提问和解答


Related Products

Relaxin 2

Periostin

PEDF Stresscorpin Adiponectin AT II Intermedin FGF-23 Urocortin BNP Endothelin Neurotensin
Urotensin II ANP Apelin PTH Obestatin Ghrelin CF-6 DNP CNP ADM Copeptin CRP
Biomarker & Treatment for Heart Failure

Clinical Relevance of Promising Novel Biomarkers.
Biomarker Diagnosis Prognosis Therapy Guidance

Roland R.J., van Kimmenade RR, James L., Clin Chem. 2012 Jan;58(1):127-38. doi: 10.1373/clinchem.2011.165720. Epub 2011 Nov 15.

The processing cascade of natriuretic peptides

Abbreviation: Glc, glycosylated;    NEP, neutral endopeptidase;     DPP-IV, dipeptidyl peptidase-IV.

Roland R.J., van Kimmenade RR, James L., Clin Chem. 2012 Jan;58(1):127-38. doi: 10.1373/clinchem.2011.165720. Epub 2011 Nov 15.

 

Prognostic value of CRP :  Frammingham risk score

Ridker el al., N Engl J Med 2002:347: 1557

 

Plasma CRP levels before and after weight loss in obese post-menopausal women (n=25)

Tchemof et al., Circulation 2002; 105: 564

 

Click to Collapse

Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial.

BACKGROUND:
Serelaxin, recombinant human relaxin-2, is a vasoactive peptide hormone with many biological and haemodynamic effects. In a pilot study, serelaxin was safe and well tolerated with positive clinical outcome signals in patients with acute heart failure. The RELAX-AHF trial tested the hypothesis that serelaxin-treated patients would have greater dyspnoea relief compared with patients treated with standard care and placebo.

METHODS:
RELAX-AHF was an international, double-blind, placebo-controlled trial, enrolling patients admitted to hospital for acute heart failure who were randomly assigned (1:1) via a central randomisation scheme blocked by study centre to standard care plus 48-h intravenous infusions of placebo or serelaxin (30 μg/kg per day) within 16 h from presentation. All patients had dyspnoea, congestion on chest radiograph, increased brain natriuretic peptide (BNP) or N-terminal prohormone of BNP, mild-to-moderate renal insufficiency, and systolic blood pressure greater than 125 mm Hg. Patients, personnel administering study drug, and those undertaking study-related assessments were masked to treatment assignment. The primary endpoints evaluating dyspnoea improvement were change from baseline in the visual analogue scale area under the curve (VAS AUC) to day 5 and the proportion of patients with moderate or marked dyspnoea improvement measured by Likert scale during the first 24 h, both analysed by intention to treat. This trial is registered at ClinicalTrials.gov, NCT00520806.

FINDINGS:
1161 patients were randomly assigned to serelaxin (n=581) or placebo (n=580). Serelaxin improved the VAS AUC primary dyspnoea endpoint (448 mm × h, 95% CI 120-775; p=0.007) compared with placebo, but had no significant effect on the other primary endpoint (Likert scale; placebo, 150 patients [26%]; serelaxin, 156 [27%]; p=0.70). No significant effects were recorded for the secondary endpoints of cardiovascular death or readmission to hospital for heart failure or renal failure (placebo, 75 events [60-day Kaplan-Meier estimate, 13.0%]; serelaxin, 76 events [13.2%]; hazard ratio [HR] 1.02 [0.74-1.41], p=0.89] or days alive out of the hospital up to day 60 (placebo, 47.7 [SD 12.1] days; serelaxin, 48.3 [11.6]; p=0.37). Serelaxin treatment was associated with significant reductions of other prespecified additional endpoints, including fewer deaths at day 180 (placebo, 65 deaths; serelaxin, 42; HR 0.63, 95% CI 0.42-0.93; p=0.019).

INTERPRETATION:
Treatment of acute heart failure with serelaxin was associated with dyspnoea relief and improvement in other clinical outcomes, but had no effect on readmission to hospital. Serelaxin treatment was well tolerated and safe, supported by the reduced 180-day mortality.

Remark:
Serelaxin (recombinant human relaxin-2 ) might be a breakthrough in the treatment of acute, decompensated HF and, after the RELAX?AHF trial, Relaxin is the first drug that seems to improve both morbidity and mortality in patients with acute, decompensated HF.

Teerlink JR et al., Lancet. 2013 Jan 5;381(9860):29-39. doi: 10.1016/S0140-6736(12)61855-8. Epub 2012 Nov 7.

Click to Expand

Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes.

Metra M et al, J Am CollCardiol. 2013 Jan 15;61(2):196-206. doi: 10.1016/j.jacc.2012.11.005.

Click to Expand

Assessment of a multimarker strategy for prediction of mortality in older heart failure patients: a cohort study.

Bjurman C et al, BMJ Open. 2013 Mar 9;3(3). pii: e002254. doi: 10.1136/bmjopen-2012-002254. Print 2013.

Click to Expand

Haemodynamic effects, safety, and pharmacokinetics of human stresscopin in heart failure with reduced ejection fraction.

Gheorghiade M et al, Eur J Heart Fail. 2013 Mar 6. [Epub ahead of print]

relaxin

%Relaxin 2%;%periostin%;%PEDF%;%Stresscopin%


分类搜索
关键字搜索
按字母搜索
A B C D E F G H I J K L M N
O P Q R S T U V W X Y Z

Copyright 2018 PHOENIX BIOTECH